The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1 G93A and TDP-43 Q331K transgenic mouse models of ALS
The glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and now next-generation multi-agonists that include GLP-1 activity, are producing average weight reductions far larger than previously expected from drugs, reshaping clinical practice and how clinicians and patients think about obesity treatment
The pharmacology of these orphan receptors displays significant overlap with CB1 and CB2, particularly for GPR18 and GPR55, although our understanding of these receptors within the respiratory system remains limited
PlexusDx clinical support reviews your health history and baseline weight to recommend a personalized timeline that balances efficacy with tolerability
Since metabolic health and mental health are closely linked, GLP-1s may provide a dual benefit for individuals struggling with both obesity and depression
Trial data showed significant triglyceride reductions with Retatrutide treatment, reflecting the interconnection between glucose and fat metabolism
